These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 22825337)

  • 1. Perifosine enhances mTORC1-targeted cancer therapy by activation of GSK3β in NSCLC cells.
    Ma Z; Zhu L; Luo X; Zhai S; Li P; Wang X
    Cancer Biol Ther; 2012 Sep; 13(11):1009-17. PubMed ID: 22825337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth.
    Koo J; Wang X; Owonikoko TK; Ramalingam SS; Khuri FR; Sun SY
    Oncotarget; 2015 Apr; 6(11):8974-87. PubMed ID: 25797247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy.
    Fu L; Kim YA; Wang X; Wu X; Yue P; Lonial S; Khuri FR; Sun SY
    Cancer Res; 2009 Dec; 69(23):8967-76. PubMed ID: 19920197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.
    Cirstea D; Hideshima T; Rodig S; Santo L; Pozzi S; Vallet S; Ikeda H; Perrone G; Gorgun G; Patel K; Desai N; Sportelli P; Kapoor S; Vali S; Mukherjee S; Munshi NC; Anderson KC; Raje N
    Mol Cancer Ther; 2010 Apr; 9(4):963-75. PubMed ID: 20371718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of mTORC1 induces loss of E-cadherin through AKT/GSK-3β signaling-mediated upregulation of E-cadherin repressor complexes in non-small cell lung cancer cells.
    Kim EY; Kim A; Kim SK; Kim HJ; Chang J; Ahn CM; Chang YS
    Respir Res; 2014 Feb; 15(1):26. PubMed ID: 24571487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
    Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
    PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin.
    Liu D; Hou P; Liu Z; Wu G; Xing M
    Cancer Res; 2009 Sep; 69(18):7311-9. PubMed ID: 19706758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel mTORC1/2 Inhibitor (MTI-31) Inhibits Tumor Growth, Epithelial-Mesenchymal Transition, Metastases, and Improves Antitumor Immunity in Preclinical Models of Lung Cancer.
    Zhang Q; Zhang Y; Chen Y; Qian J; Zhang X; Yu K
    Clin Cancer Res; 2019 Jun; 25(12):3630-3642. PubMed ID: 30796032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SNS-032 inhibits mTORC1/mTORC2 activity in acute myeloid leukemia cells and has synergistic activity with perifosine against Akt.
    Meng H; Jin Y; Liu H; You L; Yang C; Yang X; Qian W
    J Hematol Oncol; 2013 Feb; 6():18. PubMed ID: 23415012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oridonin inhibits mTOR signaling and the growth of lung cancer tumors.
    Wang YY; Lv YF; Lu L; Cai L
    Anticancer Drugs; 2014 Nov; 25(10):1192-200. PubMed ID: 25075795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation.
    Wang X; Yue P; Kim YA; Fu H; Khuri FR; Sun SY
    Cancer Res; 2008 Sep; 68(18):7409-18. PubMed ID: 18794129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin.
    Bhagwat SV; Gokhale PC; Crew AP; Cooke A; Yao Y; Mantis C; Kahler J; Workman J; Bittner M; Dudkin L; Epstein DM; Gibson NW; Wild R; Arnold LD; Houghton PJ; Pachter JA
    Mol Cancer Ther; 2011 Aug; 10(8):1394-406. PubMed ID: 21673091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination treatment with perifosine and MEK-162 demonstrates synergism against lung cancer cells in vitro and in vivo.
    Zhang J; Hong Y; Shen J
    Tumour Biol; 2015 Jul; 36(7):5699-706. PubMed ID: 25697899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary.
    Sasano T; Mabuchi S; Kuroda H; Kawano M; Matsumoto Y; Takahashi R; Hisamatsu T; Sawada K; Hashimoto K; Isobe A; Testa JR; Kimura T
    Mol Cancer Res; 2015 Apr; 13(4):795-806. PubMed ID: 25519148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway.
    Elrod HA; Lin YD; Yue P; Wang X; Lonial S; Khuri FR; Sun SY
    Mol Cancer Ther; 2007 Jul; 6(7):2029-38. PubMed ID: 17604333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.
    Sun SY; Rosenberg LM; Wang X; Zhou Z; Yue P; Fu H; Khuri FR
    Cancer Res; 2005 Aug; 65(16):7052-8. PubMed ID: 16103051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition.
    Ito H; Ichiyanagi O; Naito S; Bilim VN; Tomita Y; Kato T; Nagaoka A; Tsuchiya N
    BMC Cancer; 2016 Jul; 16():393. PubMed ID: 27387559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual Targeting of Akt and mTORC1 Impairs Repair of DNA Double-Strand Breaks and Increases Radiation Sensitivity of Human Tumor Cells.
    Holler M; Grottke A; Mueck K; Manes J; Jücker M; Rodemann HP; Toulany M
    PLoS One; 2016; 11(5):e0154745. PubMed ID: 27137757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P7170, a novel inhibitor of mTORC1/mTORC2 and Activin receptor-like Kinase 1 (ALK1) inhibits the growth of non small cell lung cancer.
    Venkatesha VA; Joshi A; Venkataraman M; Sonawane V; Bhatia D; Tannu P; Bose J; Choudhari S; Srivastava A; Pandey PK; Lad VJ; Sangana R; Ahmed T; Damre A; Deore V; Sahu B; Kumar S; Sharma S; Agarwal VR
    Mol Cancer; 2014 Dec; 13():259. PubMed ID: 25466244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acidic tumor microenvironment abrogates the efficacy of mTORC1 inhibitors.
    Faes S; Duval AP; Planche A; Uldry E; Santoro T; Pythoud C; Stehle JC; Horlbeck J; Letovanec I; Riggi N; Demartines N; Dormond O
    Mol Cancer; 2016 Dec; 15(1):78. PubMed ID: 27919264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.